Biora Therapeutics Inc. [NASDAQ: BIOR] traded at a high on 08/10/22, posting a 31.17 gain after which it closed the day’ session at $1.01. The company report on August 10, 2022 that Biora Therapeutics Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for its Targeted Therapeutics Platform.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now.
All Devices Successfully Detected Colon Entry in Patients with Active Ulcerative Colitis.
Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule (DDS) in Subjects with Ulcerative Colitis in a Fasted State.
The results of the trading session contributed to over 30907789 shares changing hands. Over the past one week, the price volatility of Biora Therapeutics Inc. stands at 16.28% while the volatility over the past one month is 9.35%.
The market cap for BIOR stock reached $167.45 million, with 183.20 million shares outstanding and 165.00 million shares in the current float. Compared to the average trading volume of 1.79M shares, BIOR reached a trading volume of 30907789 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Biora Therapeutics Inc. [BIOR]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIOR shares is $5.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIOR stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Average True Range (ATR) for Biora Therapeutics Inc. is set at 0.08, with the Price to Sales ratio for BIOR stock in the period of the last 12 months amounting to 139.54.
How has BIOR stock performed recently?
Biora Therapeutics Inc. [BIOR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 42.13. With this latest performance, BIOR shares gained by 47.12% in over the last four-week period, additionally sinking by -43.26% over the last 6 months – not to mention a drop of -44.81% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOR stock in for the last two-week period is set at 75.05, with the RSI for the last a single of trading hit 80.62, and the three-weeks RSI is set at 68.82 for Biora Therapeutics Inc. [BIOR]. The present Moving Average for the last 50 days of trading for this stock 0.7087, while it was recorded at 0.8338 for the last single week of trading, and 1.5834 for the last 200 days.
Biora Therapeutics Inc. [BIOR]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Biora Therapeutics Inc. [BIOR] shares currently have an operating margin of -9449.64 and a Gross Margin at -15.24. Biora Therapeutics Inc.’s Net Margin is presently recorded at -14316.04.
Biora Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.60.
Insider trade positions for Biora Therapeutics Inc. [BIOR]
There are presently around $51 million, or 29.70% of BIOR stock, in the hands of institutional investors. The top three institutional holders of BIOR stocks are: ATHYRIUM CAPITAL MANAGEMENT, LP with ownership of 29,855,847, which is approximately 0% of the company’s market cap and around 2.70% of the total institutional ownership; NEUBERGER BERMAN GROUP LLC, holding 6,541,060 shares of the stock with an approximate value of $6.61 million in BIOR stocks shares; and VANGUARD GROUP INC, currently with $5.21 million in BIOR stock with ownership of nearly 7.674% of the company’s market capitalization.
Positions in Biora Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 22 institutional holders increased their position in Biora Therapeutics Inc. [NASDAQ:BIOR] by around 4,966,407 shares. Additionally, 32 investors decreased positions by around 3,405,709 shares, while 16 investors held positions by with 42,101,011 shares. The mentioned changes placed institutional holdings at 50,473,127 shares, according to the latest SEC report filing. BIOR stock had 10 new institutional investments in for a total of 444,581 shares, while 19 institutional investors sold positions of 2,046,570 shares during the same period.